LON:KYGA

LON:KYGA - Kerry Group PLC

SPECULATIVE BUYREDUCE ZONEConsumer Defensive - Packaged Foods2026-08-09Data 34 days oldEUR 83.10

Conviction

out of 100

Executive Summary

Kerry Group PLC (LON:KYGA) is a global ingredients and taste solutions business that develops flavours, nutritional ingredients and sustainable proteins for food and beverage manufacturers, with the company describing itself in its 2025 Interim Management Report as a leader in taste and nutrition across more than 140 countries. Its business model is essentially business-to-business, with customers including major packaged food and beverage groups rather than end consumers, and the group operates two principal divisions in Taste & Nutrition and Consumer Foods.

The investment case rests on a stabilisation of organic volume growth, a margin recovery in Taste & Nutrition and the successful execution of an ongoing EUR 300 million share buyback programme that runs to the end of 2026. The most important near-term hard data point is the Q3 2025 trading update in which Kerry reported volume growth of 3%, in line with guidance, and the most material risk is the loss of a major customer account given the disclosed customer concentration in the company's SEC filings.

Bottom line: SPECULATIVE BUY. Conviction Score: 49/100. The rating would be upgraded on a sustained re-acceleration of organic revenue growth to mid-single digits or a clear margin expansion in Taste & Nutrition, and would be downgraded if a major customer is lost, if input cost volatility pressures gross margins further, or if Q4 2025 results show continued negative year-on-year revenue growth.

Trim / take some off. Current price EUR 83.10 is 1.3% above the trim line of EUR 82.00. Existing holders should reduce; new money should wait.

REDUCE ZONESPECULATIVE BUY · 49/100Now EUR 83.10 · buy ≤ EUR 68.67 · trim ≥ EUR 82.00

Thesis break: A confirmed loss of a named major Taste & Nutrition customer, a second consecutive quarter of double-digit negative year-on-year revenue growth, or formal suspension of the EUR 300 million buyback before end-2026 would invalidate the recovery thesis.

Business Model

Kerry Group generates the majority of its revenue from its Taste & Nutrition division, which sells flavours, functional ingredients, fermentation-derived proteins and cell-culture solutions to branded food, beverage and pharmaceutical customers globally. The Consumer Foods division, which is concentrated in Ireland and the United Kingdom, supplies dairy, meat and convenience products to retailers and foodservice operators and represents a smaller, more cyclical slice of the group. Customers are predominantly large multinational packaged food manufacturers with long-standing supply agreements, which provides revenue visibility but exposes the group to single-account concentration risk as flagged in the company's SEC filings. Competitive positioning rests on application expertise, a broad ingredient library, regulatory know-how and the ability to co-develop finished products with customers, rather than on pricing power in commoditised raw materials. Margins in Taste & Nutrition have historically been mid-teens EBITDA, with management's stated FY2025 objective of margin expansion the key swing factor for group profitability. A second layer of revenue support comes from the Consumer Foods business in Ireland and the UK, where Kerry holds number-one or strong number-two branded positions in chilled dairy, sliced meats and ready meals, but this division has been under portfolio review as the group prioritises higher-return B2B ingredients.

Financial Snapshot

Price

EUR 83.10

Market Cap

EUR 16.9bn

52w High

EUR 89.28

52w Low

EUR 64.35

Distance from 52wH

-6.9%

Avg Volume

58573

Currency

EUR

Recent Catalysts

[February 2026] - An insider purchase of 756 shares in Kerry Group by Fiona Dawson was recorded on 18 February 2026, indicating direct on-market buying by a named insider. Source: The Markets Daily.

[Q3 2025 trading update] - Kerry Group reported 3% volume growth in the third quarter of 2025, in line with company guidance, with the trading update published via the London Stock Exchange regulatory news service. Source: London Stock Exchange RNS / Investing.com.

[Q2 2025 results] - Kerry Group's Q2 2025 results showed misses on both EPS and revenue with negative year-on-year revenue growth, representing the dominant hard data point in the recent reporting cycle. Source: Company interim results, London Stock Exchange RNS.

[Ongoing 2026] - Kerry Group has been executing tranches of its EUR 300 million share buyback programme during 2026, including the settlement and cancellation of 25,000 shares which reduced the issued share count to approximately 160,117,733 ordinary shares. Source: TipRanks (citing Euronext Dublin company announcement).

[2025-08 reference] - The Kerry Group Interim Management Report 2025 was published on the London Stock Exchange, providing the framework for management's FY2025 margin expansion objective. Source: London Stock Exchange RNS.

Thesis Evaluation

Bull Case (16% weight)

Kerry delivers a sustained organic revenue re-acceleration to mid-single digits through FY2026, driven by clean-label and emerging-market demand, while Taste & Nutrition EBITDA margins expand by 50-100 basis points and the EUR 300 million buyback supports earnings per share. The combination of volume recovery and capital return drives a re-rating back towards the historical valuation range. EUR95 over 12 months.

Base Case (48% weight)

Volume growth stabilises around the 3% pace reported in Q3 2025, Taste & Nutrition margins hold rather than expand meaningfully, and the buyback programme completes by end-2026 with no major customer loss. Organic revenue growth is low single digits and the share price drifts sideways as the market waits for clearer evidence of margin recovery. EUR82 over 12 months.

Bear Case (36% weight)

A major customer account is lost or repriced, input cost volatility re-emerges, and Q4 2025 results extend the negative year-on-year revenue trend from Q2 2025, validating the bear view that the customer concentration risk disclosed in the SEC filings has crystallised. The share price revisits and then breaks the EUR64.35 52-week low. EUR62 over 12 months.

Weighted conviction:Bull (16%) x 100 + Base (48%) x 62 + Bear (36%) x 10 = 49/100. SPECULATIVE BUY.

Key Risks

Customer concentration loss: Loss or material repricing of a single major Taste & Nutrition account would have an outsized impact on group revenue given the customer concentration flagged in Kerry's SEC filings. Estimated probability: 25%. Impact: severe.
Input cost volatility: Volatility in dairy, protein and commodity ingredient costs pressures gross margins and undermines the FY2025 margin expansion objective. Estimated probability: 45%. Impact: moderate.
Continued negative organic revenue growth: If Q4 2025 and FY2026 organic revenue growth remains negative year-on-year as it did in Q2 2025, the derating extends and the 52-week low comes under pressure. Estimated probability: 35%. Impact: severe.
FX translation drag: Kerry reports in euro but derives a large share of Taste & Nutrition revenue in US dollars, sterling and emerging market currencies, so a stronger euro against the dollar creates a translation headwind. Estimated probability: 40%. Impact: moderate.
Buyback completion risk: If trading conditions deteriorate, Kerry could suspend or curtail the EUR 300 million buyback before end-2026, removing the per-share support currently embedded in the share price. Estimated probability: 15%. Impact: low.

Who Should Own It / Avoid It

Ideal for: Long-term, patient investors with at least an 18-24 month holding horizon, a moderate-to-high risk tolerance, and a willingness to underwrite cyclical B2B ingredient exposure; investors should be comfortable with negative year-on-year revenue prints and the disclosure of customer concentration risk, and should have prior experience with packaged-food names whose earnings are sensitive to input costs and FX. The position size should be sized to a speculative, recovery-style allocation rather than a core holding.

Avoid if: Investors who require positive organic growth today, who cannot tolerate a further drawdown towards the EUR64.35 52-week low, or who are sensitive to single-account customer risk should not hold this name. Short-term momentum, income-focused, and benchmark-relative investors who would be forced to sell on a continued negative revenue print are also not the right profile.

Recommendation

SPECULATIVE BUY - 49/100. Kerry Group screens as a recovery-style, deep-value packaged-foods name trading close to its 52-week low with a self-help capital return story via the EUR 300 million buyback, but conviction is held below 50 by the Q2 2025 revenue miss, the disclosed customer concentration, and the absence of new contract wins or M&A in the research data. The call would upgrade to a higher conviction tier on a return to mid-single-digit organic revenue growth, a confirmed step-up in Taste & Nutrition EBITDA margin, or an insider-buying pattern that extends beyond the small February 2026 purchase. The call would degrade to HOLD or worse on another quarter of negative year-on-year revenue growth, a major customer loss, or any suspension of the buyback programme. At the current price of EUR83.10 the shares trade at or above our base-case target of EUR82.00: the base case is fully priced, existing holders should consider trimming, and new positions are not advised above EUR68.67.

The probability-weighted value across our three scenarios is EUR76.88, 7% below the current price of EUR83.10 - the market is currently pricing the shares ahead of our probability-weighted view. Levels below are derived from the scenario targets and probabilities above, not from percentage offsets to today's price.

BUY

below EUR68.67 - below this level the upside to the base-case target (EUR82.00) is at least 2x the downside to the bear case (EUR62.00), the minimum risk/reward we require before committing new capital.

HOLD

between EUR68.67 and EUR82.00 - the base case is not yet fully priced, so existing holders are paid to wait, but new money gets no margin of safety in this zone.

REDUCE

above EUR82.00 - at this level the base case is fully reflected in the price and anything beyond it is paying for a bull scenario we weight at 16%.

SELL

if A confirmed loss of a named major Taste & Nutrition customer, a second consecutive quarter of double-digit negative year-on-year revenue growth, or formal suspension of the EUR 300 million buyback before end-2026 would invalidate the recovery thesis, regardless of price - the bear target of EUR62.00 is the backstop, not an arbitrary percentage stop.

Conviction Trend

Latest conviction: 49/100. Trend versus prior report: Down.

CONVICTION BUY (80+)BUY (65 - 79)OPP BUY (50 - 64)SPEC BUY (30 - 49)AVOID (0 - 29)

Report date	Conviction
2026-08-09	49
2026-07-25	59
2026-06-21	59
2026-05-30	60
2026-04-27	59

See the trade-card view →

Sources

Market data: DYOR HQ proprietary market data workflow.

Public sentiment and news flow: Public news flow drawing on company-published regulatory announcements (London Stock Exchange RNS, Euronext Dublin filings), company investor relations materials, financial news wires and mainstream financial press, and analyst commentary available through public aggregators.

Primary source types: SEC filings and interim management reports via the London Stock Exchange regulatory news service, company press releases, company investor relations materials, regulatory announcements of share buyback transactions on Euronext Dublin, and third-party financial news wires covering Q2 and Q3 2025 trading updates.

Key sources

Data correct as of 2026-08-09